# Trobix Innovation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trobix-innovation

- Industry: Biotechnology
- Headquarters: Netanya, Israel
- Website: www.trobix.bio
- Total disclosed funding: $6M
- Latest round: Series A (Mar 30, 2023)
- Investors on record: 1

## About

Founded in 2018 and based in Netanya, Israel, Trobix Innovation Ltd. develops innovative TBX™ products for gut-based biotherapeutics, addressing metabolic inflammatory conditions and cancer.Trobix Innovation Ltd. specializes in biotherapeutic development utilizing TBX™ products for in vivo gut production, particularly targeting metabolic and cancer-related health issues. Founded in 2018 in Netanya, Israel by Adi Elkeles, who has a history of entrepreneurship, Trobix has raised USD 3.00 mn in its Series A round on March 30, 2023, from Chartered Group. The total amount raised by the company is USD 3.00 mn across 4 investment deals.Trobix Bio specializes in the development of TBX™ products designed for in vivo gut production of biotherapeutics, targeting metabolic inflammatory conditions and cancer diseases. Their offerings leverage engineered phages for precise delivery of DNA cargo to target bacteria, facilitating innovative treatments through CRISPR and synthetic biology methodologies. These products are aimed at modifying the microbiome to enhance therapeutic outcomes, addressing issues such as transient colonization and dysbiosis. The company’s core mission is to harness the body’s own microbiome as a means for the sustained secretion of biotherapeutics, thereby ensuring robust efficacy without disrupting the microbiome’s natural composition. Trobix Bio's products are positioned primarily in the healthcare markets of North America and Europe, serving hospitals, clinics, and research institutions focusing on microbiome-related therapies.Trobix Bio engages in revenue generation through strategic partnerships and direct collaborations with healthcare providers and research institutions. The company’s business model includes agreements where clients may access TBX™ products for clinical applications in treating various diseases, particularly those affecting the microbiome. Transactions typically involve structured partnerships whereby clients secure access to product pipelines, potentially integrating TBX™ solutions into their therapeutic regimens. Pricing structures are based on the specific applications of the TBX™ products, tailored to meet the needs of institutional clients such as hospitals and research facilities. As a company focused on life-saving therapeutics, Trobix Bio emphasizes developing and maintaining long-term relationships with its clients to ensure effective implementation of its innovative solutions in the clinical landscape.In March 2023, Trobix Innovation Ltd. raised USD 3.00 mn in Series A funding from Chartered Group, as part of a larger USD 6.00 mn round. The funding will support the development of products and proprietary platform technology that addresses gastrointestinal side effects of oncology treatments and other microbiome-related diseases. Trobix plans to introduce new TBX™ products aimed at expanding therapeutic applications and intends to explore growth opportunities in additional markets in North America and Europe by the end of 2024.

## Funding rounds

- Series A, Mar 30, 2023, $3M — Chartered Group
- Series A, Jul 29, 2020, $3M — Chartered Group

## Investors

- Chartered Group (https://capitalatlas.ai/funds/chartered-group) — Series A